

HSHS Wisconsin Clinical Research Institute – Pediatric - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
ACNS1422	COG-L	NCT02724579	Brain	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
ALTE2031	COG-L	NCT04089358	Cancer Control-Other	StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
APEC14B1	COG-L	NCT02402244	Cancer Control-Other	The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
DCP-001	DCP		Cancer Control-Other	Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
EAQ202	ECOG-A	NCT05108298	Cancer Control-Other	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
AREN03B2	COG-L	NCT00898365	Kidney (Renal)	Renal Tumors Classification, Biology, and Banking Study
AREN1721	COG-AYA	NCT03595124	Kidney (Renal)	A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
ALTE03N1	COG-L	NCT00082745	Late Effects	Key Adverse Events after Childhood Cancer
ALTE05N1	COG-L	NCT00736749	Late Effects	Umbrella Long-Term Follow-Up Protocol
ALTE07C1	COG-L	NCT00772200	Late Effects	Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
AALL1631	COG-L	NCT03007147	Leukemia-Acute Lymphocytic Leukemia (ALL)	International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.
AALL1731	COG-L	NCT03914625	Leukemia-Acute Lymphocytic Leukemia (ALL)	A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
AALL1732	COG-L	NCT03959085	Leukemia-Acute Lymphocytic Leukemia (ALL)	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
ACCL20N1CD	COG-L	NCT04928599	Leukemia-Acute Lymphocytic Leukemia (ALL)	Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
ALTE1631	COG-L	NCT03223753	Leukemia-Acute Lymphocytic Leukemia (ALL)	A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
AAML1831	COG-L	NCT04293562	Leukemia-Acute Myelogenous Leukemia (AML)	A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

For more information call the HSHS Wisconsin Clinical Research Institute at (920) 433-8889.
04/30/2024

HSHS Wisconsin Clinical Research Institute – Pediatric - Active Study List

AHOD2131	COG-AYA	NCT05675410	Lymphoma-Hodgkin's	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immunology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
EAQ211	ECOG-A	NCT06002828	Lymphoma-Hodgkin's	Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
ACCL21C2	COG-L	NCT05228275	Multiple Disease Sites	Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
AGCT1531	COG-AYA	NCT03067181	Multiple Disease Sites	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
ANBL1531	COG-L	NCT03126916	Neuroblastoma	A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
AGCT1532	COG-AYA	NCT02582697	Solid Tumor-Other	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors